In the future, we’ll hopefully be able to “biopsy” a cancer patient’s immune system and cancer sample, then use an algorithm to determine their optimal therapy.
While we’re not quite there, we’ve made incredible strides in cancer treatment, even in the last 5 years alone. And a fundamental reason for this progress is clinical trials.
Thomas Marron, MD., PhD., Director of the Early Phase Trials Unit at Tisch Cancer Institute. From informed consent to placebos to collecting samples, we took a deep dive into the questions, concerns, and experiences of oncology patients involved in clinical trials.
Learn about the biggest advancements in the field, as well as how you can help educate and support patients in your practice who are considering or undergoing a clinical trial.
Here are the show highlights
- How immunotherapy is changing the game for cancer patients (4:23
- What the 3 phases of clinical trials focus on (8:15
- How he answers the most common patient questions (11:10)
- Why it’s necessary to do a lot of blood tests — and no, it’s not because they’re vampires! (16:15)
- 5,000 new cancer therapies and counting (23:16)
Stay connected with Working in Oncology on Apple Podcasts, Spotify, or our podcast website.
Guest Bio
Thomas Marron, MD., PHd is the Director of Early Phase Trials Unit at the Tisch Cancer Institute and Assistant Professor of Medicine at the Icahn School of Medicine. He is currently involved in over four dozen clinical trials.
